Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Cobra Biologics and Novolytics Develop Bacteriophages Against Infection

Published: Wednesday, June 12, 2013
Last Updated: Wednesday, June 12, 2013
Bookmark and Share
Companies have achieved a breakthrough in the development of two Staphylococcus aureus-based phage products for Phase I clinical trials.

An existing process was transferred to Cobra’s phage team and a scope of work undertaken to further develop the process to increase yields for the two Staphylococcus aureus-based phage products. The controlled, high yield process provides Novolytics with a clear path forward to producing suitable GMP material for human clinical trials.

The worldwide emergence of ‘superbugs’ such as MRSA has coincided with the virtual drying up of new antibiotic drug development. Novolytics aims to lead the way in utilising nature’s own natural antidote, bacteriophages. The company’s lead product, NOVO12, is a phage cocktail administered as a gel for topical treatment of MRSA infections.

Cobra is set to present its methodology, approach, and acquired expertise in phage manufacture at the Phages 2013 conference taking place in Oxford, UK, in September 2013.

‘It is very exciting to be engaged with such novel phage products and to be actively assisting pioneering companies like Novolytics to introduce ground-breaking anti-infectives,’ said Peter Coleman, CEO of Cobra Biologics. ‘The phage team has considerable experience in developing processes for such novel products and looks forward to working closely with Novolytics.’

Novolytics CEO John Hardcastle added: ‘Cobra is helping Novolytics to produce bacteriophage cocktails that remain therapeutically active when produced to GMP standard and on an industrial scale. This is a critical factor for successful exploitation of the exciting potential that phage therapy offers.’

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cobra Biologics Appointed by University of Sheffield
Manufacturing service will scale production of growth hormone developed using ‘ProFuse’ Technology.
Tuesday, November 24, 2015
Cobra Biologics, The University of Manchester Announce Collaboration
Agreement brings together academic and industrial expertise for the scaled manufacture of therapeutic proteins.
Friday, September 25, 2015
Cobra Biologics and The University of Manchester Announce Collaboration
Agreement brings together academic and industrial expertise for the scaled manufacture of therapeutic proteins.
Friday, September 25, 2015
Cobra Biologics and Tecrea Awarded £112K Innovate UK Grant to Develop AAV Scalable Production Bioprocess
‘Technology Inspired Innovation’ award to evaluate robust, large scale viral vector production.
Thursday, April 02, 2015
Cobra Biologics & The University of Manchester Receive £217K Innovate UK/BBSRC Funding
Awarded as part of £20M competition bringing innovative biotechnology projects to market.
Monday, February 23, 2015
Cobra Biologics Appoints CSO
Company announces the appointment of Dr Daniel C. Smith as its Chief Scientific Officer.
Wednesday, May 07, 2014
Cobra Biologics, BioCancell Agreement for Promising Cancer Therapy Drug
The Companies have announced the agreement to manufacture BioCancell’s BC-821 cancer drug for clinical trials.
Monday, March 03, 2014
GMP Certification Boost for Cobra Biologics
Extended certification to include QC testing of registered products.
Wednesday, February 12, 2014
Cobra Biologics and Recopharma Enter Agreement
Agreement to utilize Cobra’s cell line development service- MaxXpress.
Wednesday, May 29, 2013
Cobra Biologics and Vaccibody Sign Agreement to Manufacture DNA Vaccine
Companies announce agreement to manufacture Vaccibody’s lead DNA vaccine candidate against HPV-induced malignancies.
Tuesday, May 14, 2013
Scientific News
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos